Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02634177 · ClinicalTrials.gov registry record · NA
Genecept Assay™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With MDD
A NA study of Major Depressive Disorder, sponsored by Genomind.
- Completed
- Registry status
- NA
- Development phase
- 305
- Enrollment target
- 20
- Study locations
NCT02634177 is a NA study of Major Depressive Disorder that has completed, run by Genomind. The registered enrollment target is 305 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (19% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT02634177, a NA study of Major Depressive Disorder, has completed, sponsored by Genomind.
- COMPLETED
- Registry status
- NA
- Development phase
- 305 participants
- Enrollment target
- 20
- Study locations
Study Summary
In this randomized clinical trial, subjects will be assigned to either an assay-guided treatment condition (AGT) or a treatment-as-usual condition (TAU). All subjects will provide a DNA sample at the Screening Visit for the Genecept Assay ™. In the AGT condition, assay results will be provided to the treating investigator, who will use the results to guide antidepressant pharmacotherapy. In the TAU condition, the investigator will treat the subjects without the knowledge of the pharmacogenetic testing results. Assay results for all subjects will be provided to the investigator once all Week 8 visit procedures have been completed. Raters of the primary endpoint assessment and subjects will remain blinded to treatment assignment.
Conditions Studied
Interventions
- OTHER Treatment-as-usual (TAU)
- GENETIC Assay-guided treatment (AGT)
Study Locations (20)
California
- Collaborative Neuroscience Network, Inc. - Garden Grove - Garden Grove
- Pacific Institute of Medical Research - Los Angeles
- Pacific Research Partners, LLC - Oakland
- Artemis Institute for Clinical Research - San Diego
- Collaborative Neuroscience Network, Inc. - Torrance - Torrance
- Pacific Clinical Research Medical Group - Upland
Florida
- Florida Clinical Research Center, LLC - Bradenton - Bradenton
- Clinical Neuroscience Solutions Inc. - Jacksonville - Jacksonville
- Florida Clinical Research Center, LLC - Maitland - Maitland
- Clinical Neuroscience Solutions Inc. - Orlando - Orlando
Alabama
- University of Alabama - Birmingham - Birmingham
Arizona
- Noesis Pharma - Phoenix
Arkansas
- Woodland Research Northwest - Springdale
Illinois
- Chicago Research Center, Inc. - Chicago
Massachusetts
- Boston Clinical Trials - Boston
Nebraska
- Premier Psychiatric Research Institute, LLC - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 305 participants |
| Start Date | 2016-01 |
| Est. Completion | 2017-07-25 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02634177
The ClinicalTrials.gov registry entry for NCT02634177 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 305 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (19% lower). The listed sponsor is Genomind, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Treatment-as-usual (TAU) is the first listed.
NCT02634177 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT02634177 about?
NCT02634177 is a clinical study titled "Genecept Assay™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With MDD". In this randomized clinical trial, subjects will be assigned to either an assay-guided treatment condition (AGT) or a treatment-as-usual condition (TAU). All subjects will provide a DNA sample at the Screening Visit for the Genecept Assay ™. In the AGT condition, assay results will be provided to th...
What is the current status of trial NCT02634177?
This trial is currently completed. It is a NA study. The enrollment target is 305 participants. The study started on 2016-01. Estimated completion is 2017-07-25.
What conditions does trial NCT02634177 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT02634177?
The interventions under investigation include: Treatment-as-usual (TAU) (OTHER), Assay-guided treatment (AGT) (GENETIC).
Who is sponsoring clinical trial NCT02634177?
This trial is sponsored by Genomind, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02634177 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Taking Action for College Students
RECRUITING · NA
-
Targeting Large-scale Networks in Depression With Real-time Functional Magnetic Resonance Imaging (fMRI) Neurofeedback
RECRUITING · NA
-
Neural Correlates of Stress and Perceived Control in Adolescent Depression
RECRUITING · NA
-
Positive Processes and Transition to Health (PATH)
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Amygdala Neurofeedback for Depression - Large Scale Clinical Trial
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.